Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
HCV direct-acting antivirals revolutionized the treatment outcomes especially in areas considered to be highly
endemic as Egypt, where the government adopted a National Treatment Program and successfully reached
a large sector of the HCV patient’s population. High response rate to treatment with Sofosbuvir and Daclatasvir
necessitated confirmation of total cure through excluding HCV occult infection. Our aim was to estimate the
occurrence of occult HCV in patients treated with Sofosbuvir and Daclatasvir, by detecting HCV RNA in their
PBMCs. Quantitative estimation of HCV viral load in serum samples and PBMCs of 40 patients undergoing
treatment with Sofosbuvir and Daclatasvir, was done using COBAS AmpliprepTM/COBAS TaqManTM. At the start
of treatment serum samples were positive for HCV RNA (ranged from 2.50x103-6101.0x103). After one month of
the treatment our data revealed that serum HCV RNA was negative by PCR. After three months, HCV RNA was
detected in PBMCs in 10 out of 40 via RT-PCR. Comparison between the results of HCV RNA in serum and PBMCs
by PCR after three months of treatment, showed statistically significant difference of p=0.001. This reveals the high
prevalence of HCV RNA in PBMCs denoting occult HCV infection after combined treatment with Sofosbuvir and
Daclatasvir. It also signifies that although the combined treatment was effective in eliminating the virus from the
serum, it is less effective in its elimination from the PBMCs. These results also highlight the importance of testing for
HCV RNA in PBMCs after end of treatment to confirm total HCV elimination.